Evidence map›Paper›PMID 26469189›Full record

ArticlePloS one2015

Comparison of 454 Ultra-Deep Sequencing and Allele-Specific Real-Time PCR with Regard to the Detection of Emerging Drug-Resistant Minor HIV-1 Variants after Antiretroviral Prophylaxis for Vertical Transmission.

Andrea Hauser, Claudia Kuecherer, Andrea Kunz, Piotr Wojtek Dabrowski, Aleksandar Radonić, Andreas Nitsche, Stefanie Theuring, Norbert Bannert, Julius Sewangi, Paulina Mbezi and 3 more

Open access · goldAbstract readComparative StudyEvaluation Study
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.6field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Article
  3. What is new in perinatal HIV prevention?Current opinion in pediatrics · 2018
    Review
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 2 countries.

Andrea HauserHIV and other Retroviruses, Robert Koch-Institute, Berlin, Germany.
Claudia KuechererHIV and other Retroviruses, Robert Koch-Institute, Berlin, Germany.
Andrea KunzInstitute of Tropical Medicine and International Health, Charité - Universitätsmedizin Berlin, Berlin, Germany.
Piotr Wojtek DabrowskiCentre for Biological Threats and Special Pathogens 1, Highly Pathogenic Viruses, Robert Koch-Institute, Berlin, Germany.
Aleksandar RadonićCentre for Biological Threats and Special Pathogens 1, Highly Pathogenic Viruses, Robert Koch-Institute, Berlin, Germany.
Andreas NitscheCentre for Biological Threats and Special Pathogens 1, Highly Pathogenic Viruses, Robert Koch-Institute, Berlin, Germany.
Stefanie TheuringInstitute of Tropical Medicine and International Health, Charité - Universitätsmedizin Berlin, Berlin, Germany.
Norbert BannertHIV and other Retroviruses, Robert Koch-Institute, Berlin, Germany.
Julius SewangiRegional AIDS Control Program Mbeya Region, Ministry of Health and Social Welfare, Dar es Salaam, Tanzania.
Paulina MbeziPMTCT Service Mbeya Region, Ministry of Health and Social Welfare, Dar es Salaam, Tanzania.
Festo DugangeKyela District Hospital, Ministry of Health and Social Welfare, Dar es Salaam, Tanzania.
Gundel HarmsInstitute of Tropical Medicine and International Health, Charité - Universitätsmedizin Berlin, Berlin, Germany.
Karolin MeixenbergerHIV and other Retroviruses, Robert Koch-Institute, Berlin, Germany.
Robert Koch Institute · DECharité - Universitätsmedizin Berlin · DEMinistry of Health and Social Welfare · TZ

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPregnant HIV-infected women were screened for the development of HIV-1 drug resistance after implementation of a triple-antiretroviral transmission prophylaxis as recommended by the WHO in 2006. The study offered the opportunity to compare amplicon-based 454 ultra-deep sequencing (UDS) and allele-specific real-time PCR (ASPCR) for the detection of drug-resistant minor variants in the HIV-1 reverse transcriptase (RT).

methodsPlasma samples from 34 Tanzanian women were previously analysed by ASPCR for key resistance mutations in the viral RT selected by AZT, 3TC, and NVP (K70R, K103N, Y181C, M184V, T215Y/F). In this study, the RT region of the same samples was investigated by amplicon-based UDS for resistance mutations using the 454 GS FLX System.

resultsDrug-resistant HIV-variants were identified in 69% (20/29) of women by UDS and in 45% (13/29) by ASPCR. The absolute number of resistance mutations identified by UDS was twice that identified by ASPCR (45 vs 24). By UDS 14 of 24 ASPCR-detected resistance mutations were identified at the same position. The overall concordance between UDS and ASPCR was 61.0% (25/41). The proportions of variants quantified by UDS were approximately 2-3 times lower than by ASPCR. Amplicon generation from samples with viral loads below 20,000 copies/ml failed more frequently by UDS compared to ASPCR (limit of detection = 650 copies/ml), resulting in missing or insufficient sequence coverage.

conclusionsBoth methods can provide useful information about drug-resistant minor HIV-1 variants. ASPCR has a higher sensitivity than UDS, but is restricted to single resistance mutations. In contrast, UDS is limited by its requirement for high viral loads to achieve sufficient sequence coverage, but the sequence information reveals the complete resistance patterns within the genomic region analysed. Improvements to the UDS limit of detection are in progress, and UDS could then facilitate monitoring of drug-resistant minor variants in the HIV-1 quasispecies.

Indexed as

AllelesAnti-HIV AgentsDrug Resistance, ViralFemaleHigh-Throughput Nucleotide SequencingHIV-1HIV InfectionsHumansInfectious Disease Transmission, VerticalMutationPost-Exposure ProphylaxisPregnancyPregnancy Complications, InfectiousPrognosisReal-Time Polymerase Chain ReactionTanzaniaAnti-HIV Agents

Identifiers

PMID26469189
PMCPMC4607442
OpenAlexW2192835292

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.